{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:43:23Z","timestamp":1792806203181,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016304","name":"Medtronic Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.diabres.2026.113442","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:58:43Z","timestamp":1784530723000},"page":"113442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Variability in magnitude and direction of discordance between continuous glucose monitoring (CGM) metrics and traditional biomarkers in patients with diabetes and end-stage kidney disease (ESKD): A case series"],"prefix":"10.1016","volume":"239","author":[{"given":"Yunyao","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze Kit","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk Chun","family":"Szeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack KC","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113442_b0005","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work G. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1\u2013S127. doi: 10.1016\/j.kint.2022.06.008. PubMed PMID: 36272764.","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"10.1016\/j.diabres.2026.113442_b0010","doi-asserted-by":"crossref","unstructured":"Gomez-Peralta F, Choudhary P, Cosson E, Irace C, Rami-Merhar B, Seibold A. Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin. Diabetes Obes Metab. 2022;24(4):599\u2013608. Epub 20220208. doi: 10.1111\/dom.14638. PubMed PMID: 34984825.","DOI":"10.1111\/dom.14638"},{"key":"10.1016\/j.diabres.2026.113442_b0015","doi-asserted-by":"crossref","unstructured":"Zelnick LR, Trikudanathan S, Hall YN, Ayers E, Anderson L, Ashford N, et al. Accuracy, Variability, and Bias of Glycemic Biomarkers in Patients Treated With Maintenance Dialysis. Diabetes Care. 2026;49(5):835-42. doi: 10.2337\/dc25-2952. PMID: 41805834; PMCID: PMC13094876.","DOI":"10.2337\/dc25-2952"},{"key":"10.1016\/j.diabres.2026.113442_b0020","doi-asserted-by":"crossref","unstructured":"Galindo RJ, Soliman D, Chernavvsky D, Rhee CM. Diabetes technology in people with diabetes and advanced chronic kidney disease. Diabetologia. 2024;67(10):2129\u201342. Epub 20240808. doi: 10.1007\/s00125-024-06244-y. PubMed PMID: 39112642; PubMed Central PMCID: PMC11446991.","DOI":"10.1007\/s00125-024-06244-y"},{"key":"10.1016\/j.diabres.2026.113442_b0025","doi-asserted-by":"crossref","unstructured":"Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019;42(3):400\u20135. Epub 20181023. doi: 10.2337\/dc18-1444. PubMed PMID: 30352896; PubMed Central PMCID: PMC6905478.","DOI":"10.2337\/dc18-1444"},{"key":"10.1016\/j.diabres.2026.113442_b0030","unstructured":"Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593\u2013603. Epub 20190608. doi: 10.2337\/dci19-0028. PubMed PMID: 31177185; PubMed Central PMCID: PMC6973648."},{"key":"10.1016\/j.diabres.2026.113442_b0035","doi-asserted-by":"crossref","unstructured":"Gai M, Merlo I, Dellepiane S, Cantaluppi V, Leonardi G, Fop F, et al. Glycemic pattern in diabetic patients on hemodialysis: continuous glucose monitoring (CGM) analysis. Blood Purif. 2014;38(1):68\u201373. Epub 20141007. doi: 10.1159\/000362863. PubMed PMID: 25300368.","DOI":"10.1159\/000362863"},{"key":"10.1016\/j.diabres.2026.113442_b0040","doi-asserted-by":"crossref","unstructured":"de Boer IH, Anderson LD, Ashford NK, Ayers E, Bansal N, Hall YN, et al. Glycemia Assessed by Continuous Glucose Monitoring among People Treated with Maintenance Dialysis. J Am Soc Nephrol. 2025;36(9):1798\u2013810. Epub 20250321. doi: 10.1681\/asn.0000000693. PubMed PMID: 40117214; PubMed Central PMCID: PMC12416938.","DOI":"10.1681\/ASN.0000000693"},{"issue":"4","key":"10.1016\/j.diabres.2026.113442_b0045","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1210\/er.2018-00284","article-title":"Potential Clinical Error Arising from use of HbA1c in Diabetes: Effects of the Glycation Gap","volume":"40","author":"Nayak","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.diabres.2026.113442_b0050","doi-asserted-by":"crossref","unstructured":"Hempe JM, Yang S, Liu S, Hsia DS. Standardizing the haemoglobin glycation index. Endocrinol Diabetes Metab. 2021;4(4):e00299. Epub 20210923. doi: 10.1002\/edm2.299. PubMed PMID: 34558807; PubMed Central PMCID: PMC8502217.","DOI":"10.1002\/edm2.299"},{"key":"10.1016\/j.diabres.2026.113442_b0055","doi-asserted-by":"crossref","unstructured":"Nayak AU, Nevill AM, Bassett P, Singh BM. Association of glycation gap with mortality and vascular complications in diabetes. Diabetes Care. 2013;36(10):3247\u201353. Epub 20130708. doi: 10.2337\/dc12-1040. PubMed PMID: 23835697; PubMed Central PMCID: PMC3781552.","DOI":"10.2337\/dc12-1040"},{"issue":"3","key":"10.1016\/j.diabres.2026.113442_b0060","first-page":"127","article-title":"Comparison of fructosamine with glycated hemoglobin as an index of glycemic control in diabetic patients","volume":"13","author":"Guillausseau","year":"1990","journal-title":"Diabetes Res"},{"key":"10.1016\/j.diabres.2026.113442_b0065","doi-asserted-by":"crossref","unstructured":"\u00c7etinkaya Altunta\u015f S, Evran M, G\u00fcrkan E, Sert M, Tetiker T. HbA1c level decreases in iron deficiency anemia. Wien Klin Wochenschr. 2021;133(3-4):102\u20136. Epub 20200506. doi: 10.1007\/s00508-020-01661-6. PubMed PMID: 32377869.","DOI":"10.1007\/s00508-020-01661-6"},{"key":"10.1016\/j.diabres.2026.113442_b0070","doi-asserted-by":"crossref","unstructured":"Ling J, Ng JKC, Lau ESH, Luk AOY, Ma RCW, Vigersky RA, et al. Impact of Body Composition and Anemia on Accuracy of a Real-Time Continuous Glucose Monitor in Diabetes Patients on Continuous Ambulatory Peritoneal Dialysis. Diabetes Technol Ther. 2024;26(1):70\u20135. Epub 20231127. doi: 10.1089\/dia.2023.0349. PubMed PMID: 37955697.","DOI":"10.1089\/dia.2023.0349"},{"key":"10.1016\/j.diabres.2026.113442_b0075","doi-asserted-by":"crossref","unstructured":"Lee SY, Chen YC, Tsai IC, Yen CJ, Chueh SN, Chuang HF, et al. Glycosylated hemoglobin and albumin-corrected fructosamine are good indicators for glycemic control in peritoneal dialysis patients. PLoS One. 2013;8(3):e57762. Epub 20130304. doi: 10.1371\/journal.pone.0057762. PubMed PMID: 23469230; PubMed Central PMCID: PMC3587617.","DOI":"10.1371\/journal.pone.0057762"},{"key":"10.1016\/j.diabres.2026.113442_b0080","doi-asserted-by":"crossref","unstructured":"Lenters-Westra E, Fokkert M, Kilpatrick ES, Schleicher E, Pilla S, English E, et al. Managing discordance between HbA(1c) and glucose management indicator. Diabet Med. 2025;42(6):e70023. Epub 20250323. doi: 10.1111\/dme.70023. PubMed PMID: 40123266; PubMed Central PMCID: PMC12080991.","DOI":"10.1111\/dme.70023"},{"issue":"1","key":"10.1016\/j.diabres.2026.113442_b0085","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2337\/diacare.26.1.163","article-title":"Discordance between HbA1c and Fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy","volume":"26","author":"Cohen","year":"2003","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2026.113442_b0090","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2337\/diacare.27.6.1259","article-title":"Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes","volume":"27","author":"McCarter","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113442_b0095","doi-asserted-by":"crossref","unstructured":"Puig-Jov\u00e9 C, Vi\u00f1als C, Conget I, Quir\u00f3s C, Vinagre I, Berrocal B, et al. Association between the GMI\/HbA1c ratio and preclinical carotid atherosclerosis in type 1 diabetes: impact of the fast-glycator phenotype across age groups. Cardiovasc Diabetol. 2025;24(1):75. Epub 20250214. doi: 10.1186\/s12933-025-02637-4. PubMed PMID: 39953520; PubMed Central PMCID: PMC11829493.","DOI":"10.1186\/s12933-025-02637-4"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:17:16Z","timestamp":1792804636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726003621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":19,"alternative-id":["S0168822726003621"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113442","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variability in magnitude and direction of discordance between continuous glucose monitoring (CGM) metrics and traditional biomarkers in patients with diabetes and end-stage kidney disease (ESKD): A case series","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113442"}}